Tyler Van Buren
Stock Analyst at TD Cowen
(3.14)
# 1,131
Out of 5,162 analysts
63
Total ratings
47.06%
Success rate
2.11%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Buy | $15 → $30 | $9.58 | +213.15% | 4 | Mar 11, 2026 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $120 → $85 | $33.76 | +151.81% | 1 | Feb 26, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $35 | $22.75 | +53.85% | 1 | Feb 26, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $40 → $45 | $48.75 | -7.69% | 3 | Feb 13, 2026 | |
| CCCC C4 Therapeutics | Initiates: Buy | n/a | $2.72 | - | 1 | Dec 2, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | n/a | $28.00 | - | 1 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $30 → $40 | $27.80 | +43.88% | 2 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $95 | $69.41 | +36.87% | 2 | Oct 30, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $115 → $125 | $144.99 | -13.79% | 6 | Oct 23, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | n/a | $33.09 | - | 1 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $64.29 | - | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $11.02 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $19.19 | - | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $40.00 | - | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $70 → $60 | $52.56 | +14.16% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $6.18 | - | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $7.39 | - | 1 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,030 → $1,200 | $745.77 | +60.91% | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $33.31 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $28.62 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $39.89 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $114.39 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $71.90 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.17 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $30.86 | +126.83% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.71 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.18 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $36.22 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $11.29 | +1,892.91% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $7.57 | +11,458.78% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $15.04 | +165.96% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $13.78 | +117.71% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.35 | +3,603.70% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.44 | +6,763.42% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.19 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $28.57 | - | 1 | Aug 4, 2017 |
Biohaven
Mar 11, 2026
Maintains: Buy
Price Target: $15 → $30
Current: $9.58
Upside: +213.15%
Soleno Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $120 → $85
Current: $33.76
Upside: +151.81%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $35
Current: $22.75
Upside: +53.85%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Hold
Price Target: $40 → $45
Current: $48.75
Upside: -7.69%
C4 Therapeutics
Dec 2, 2025
Initiates: Buy
Price Target: n/a
Current: $2.72
Upside: -
MBX Biosciences
Nov 4, 2025
Initiates: Buy
Price Target: n/a
Current: $28.00
Upside: -
Travere Therapeutics
Oct 31, 2025
Maintains: Buy
Price Target: $30 → $40
Current: $27.80
Upside: +43.88%
BridgeBio Pharma
Oct 30, 2025
Maintains: Buy
Price Target: $60 → $95
Current: $69.41
Upside: +36.87%
Gilead Sciences
Oct 23, 2025
Maintains: Buy
Price Target: $115 → $125
Current: $144.99
Upside: -13.79%
IDEAYA Biosciences
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $33.09
Upside: -
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $64.29
Upside: -
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $11.02
Upside: -
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $19.19
Upside: -
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $40.00
Upside: -
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $52.56
Upside: +14.16%
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $6.18
Upside: -
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $7.39
Upside: -
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $745.77
Upside: +60.91%
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $33.31
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $28.62
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $39.89
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $114.39
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $71.90
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.17
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $30.86
Upside: +126.83%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.71
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.18
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $36.22
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $11.29
Upside: +1,892.91%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $7.57
Upside: +11,458.78%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $15.04
Upside: +165.96%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $13.78
Upside: +117.71%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.35
Upside: +3,603.70%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $0.44
Upside: +6,763.42%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $11.19
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $28.57
Upside: -